Special edition

In this deep dive BioSpace analyzes the neuropsychedelic therapeutics pipeline, which grabbed headlines in February when the FDA accepted the New Drug Application for Lykos Therapeutics’ MDMA capsules for PTSD.

In this deep dive, BioSpace takes a closer look at the drug price crisis in the U.S. As President Joe Biden and former President Donald Trump gear up for a rematch in the 2024 election, we explore how federal reforms to lower costs could be leveraged on the campaign trail.

The job response rate has risen year over year, according to BioSpace data, indicating competition for roles posted on our website has increased.

In this deep dive, BioSpace examines what’s next for Leqembi, the true cost of anti-amyloid antibodies, and what other Alzheimer’s treatments are coming down the pipeline.

If it feels like there has never been a tougher time to look for work, you’re not alone—and you’re likely not wrong.

In this deep dive, BioSpace examines how small, medium and large companies are using artificial intelligence and machine learning to enhance their drug discovery efforts.

In this job market report we’re reviewing life sciences job market movement in Q3 and what to expect for Q4 and beyond.

In this special report, BioSpace examines how the biopharma industry is grappling with impending consequences of the Inflation Reduction Act.